The histopathological mimics of inflammatory bowel disease: a critical appraisal

Woodman, Isabel; Schofield, J. B.; Haboubi, Najib

doi:10.1007/s10151-015-1372-8

Cited by 15 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathological diagnosis of inflammatory bowel disease is often difficult because biopsy material may not contain pathognomonic features, making distinction between Crohn’s disease, ulcerative colitis and other forms of colitides a truly challenging exercise. The best way for reliant diagnosis is multidisciplinary approach when the full clinical history, endoscopic findings, radiology and relevant serology and microbiology are available (Woodman et al 2015 ; Şimşek et al 2016 ). This can be very important in patients with IBD because early anti-amebic therapy is essential and significantly influence on the course of disease.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of amebiasis in inflammatory bowel disease in University Clinical Hospital Mostar

et al. 2016

View full text Add to dashboard Cite

AimTo explore the prevalence of amebiasis in inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, in patients in Clinical hospital Mostar (Bosnia and Herzegovina, region of Herzegovina).MethodsIn this study, Entamoeba histolytica/dispar prevalence was investigated in fresh faeces by native microscopy and immunochromatographic rapid assay “RIDA®QUICK Entamoeba test”, in 119 cases of new found IBD patients, 84 of ulcerative colitis and 35 of Crohn’s disease and in control group who had also 119 patients who didn’t have any gastrointestinal complaints. IBD diagnosis was established by standard diagnostic procedures (anamnesis, clinical manifestations, laboratory, endoscopy and biopsy).ResultsEntamoeba histolytica/dispar were found in 19 (16.0 %) of a total of 119 cases, 12 (14.3 %) of the 84 patients with ulcerative colitis and 7 (20.0 %) of the 35 patients with Crohn’s disease. As for the 119 patients in the control group who had not any gastrointestinal complaints, 2 (1.7 %) patients were found to have E. histolytica/dispar in their faeces. Amoeba prevalence in the patient group was determined to be significantly higher in group with Crohn’s disease, ulcerative colitis and IBD total than in the control group (p < 0.001).ConclusionAmeba infections in patients with Crohn’s disease and ulcerative colitis, have a greater prevalence compared to the normal population.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of amebiasis in inflammatory bowel disease in University Clinical Hospital Mostar

et al. 2016

View full text Add to dashboard Cite

show abstract

“…An immune reaction of transplanted bone marrow cells against the recipient underlies this condition. In intestinal graft versus host disease, the histological pattern may mimic both celiac disease (IEL accumulation and villous atrophy) and inflammatory bowel disease (ulcerations, cryptitis, crypt abscesses), thus prompting a differential diagnosis [120-122]. …”

Section: Origin Of Mementioning

confidence: 99%

Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?

Ierardi¹,

Losurdo²,

Iannone³

et al. 2017

aog

View full text Add to dashboard Cite

Microscopic enteritis (ME) is characterized by abnormal infiltration of intraepithelial lymphocytes in intestinal mucosa. It was described as duodenal lymphocytosis or lymphocytic duodenitis until the dedicated Consensus Conference of 2015. ME represents a common feature of several gluten-mediated and non-gluten related diseases; therefore, it is an umbrella term embracing several conditions. The most frequent causes of ME are gluten-related disorders (celiac disease, non-celiac gluten sensitivity, wheat allergy), Helicobacter pylori infection and drug-related damages. Less frequently, ME may be secondary to inflammatory bowel disease, some autoimmune conditions, immunoglobulin deficiencies, blood malignancies, infections and irritable bowel syndrome. Therefore, the differential diagnosis of ME may be challenging. The diagnosis of ME needs to be driven by predominant symptoms and patient history. However, it is often difficult to achieve an immediate identification of the underlying condition, and a broad variety of diagnostic tests may be required. Ultimately, long-term surveillance is needed for a final diagnosis in many cases, since a hidden or quiescent condition may be disclosed after a period of latency. In any case, strict collaboration between the clinician and the pathologist is pivotal. The treatment of ME should be personalized, depending on the underlying disease. For gluten-related conditions (celiac disease, gluten sensitivity, wheat allergy, dermatitis herpetiformis), a gluten-free diet may be proposed. For other conditions, a targeted etiologic treatment is necessary. In conclusion, ME represents a novel entity that is attracting increasing interest. The growing epidemiologic trend confirms that it will become a common condition in clinical practice.

show abstract

“…49 Certainly some infections cause a phenotype similar to IBD (e.g. intestinal tuberculosis, Campylobacter jejuni, Yersinia enterocolitica and others), 50,51 raising the possibility that some subsets of IBD are actually unrecognized intestinal infections. Some potential examples include, Mycobacterium avium subsp.…”

Section: Specific Bacteria Are Associated With Ibdmentioning

confidence: 99%

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

2017

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a complex set of diseases that lead to chronic inflammation in the gastrointestinal tract. Although the etiology of IBD is not fully understood, it is well-known that the intestinal microbiota is associated with the development and maintenance of IBD. Manipulation of the gut microbiota, therefore, may represent a target for IBD therapy. Fecal microbiota transplantation (FMT), where fecal microbiota from a healthy donor is transplanted into a patient's GI tract, is already a successful therapy for Clostridium difficile infection. FMT is currently being explored as a potential therapy for IBD as well. In this review, the associations between the gut microbiota and IBD and the emerging data on FMT for IBD will be discussed.

show abstract

The histopathological mimics of inflammatory bowel disease: a critical appraisal

Cited by 15 publications

References 46 publications

Prevalence of amebiasis in inflammatory bowel disease in University Clinical Hospital Mostar

Prevalence of amebiasis in inflammatory bowel disease in University Clinical Hospital Mostar

Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

Contact Info

Product

Resources

About